Westhampton Capital’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,330
Closed -$345K 117
2024
Q1
$345K Sell
4,330
-600
-12% -$45.8K 0.19% 98
2023
Q4
$389K Sell
4,930
-1,400
-22% -$99.6K 0.23% 94
2023
Q3
$442K Sell
6,330
-1,571
-20% -$111K 0.28% 86
2023
Q2
$546K Sell
7,901
-199
-2% -$14.2K 0.35% 74
2023
Q1
$602K Buy
8,100
+230
+3% +$19.3K 0.39% 73
2022
Q4
$733K Sell
7,870
-630
-7% -$60.8K 0.5% 65
2022
Q3
$811K Sell
8,500
-130
-2% -$12.9K 0.61% 57
2022
Q2
$800K Buy
8,630
+50
+0.6% +$4.88K 0.57% 57
2022
Q1
$868K Buy
8,580
+50
+0.6% +$5.25K 0.56% 58
2021
Q4
$880K Hold
8,530
0.54% 57
2021
Q3
$724K Hold
8,530
0.5% 64
2021
Q2
$712K Hold
8,530
0.46% 66
2021
Q1
$642K Buy
8,530
+4,420
+108% +$322K 0.44% 65
2020
Q4
$281K Sell
4,110
-3,800
-48% -$247K 0.21% 92
2020
Q3
$462K Hold
7,910
0.38% 71
2020
Q2
$514K Sell
7,910
-200
-2% -$12.6K 0.45% 65
2020
Q1
$481K Sell
8,110
-10
-0.1% -$668 0.5% 60
2019
Q4
$603K Buy
8,120
+200
+3% +$14K 0.49% 58
2019
Q3
$500K Buy
7,920
+1,375
+21% +$81.5K 0.42% 65
2019
Q2
$357K Buy
+6,545
New +$352K 0.3% 82

Other funds holding CVS

Westhampton Capital's CVS Position: Q2 2024 in Review

Westhampton Capital sold out of CVS Health (CVS) in Q2 2024, closing a stake of 4,330 shares — an estimated $345K sold.

Westhampton Capital first reported a position in CVS in Q2 2019 and held it in 20 quarters. The position peaked at $880K in Q4 2021. 1,910 funds tracked by Wall St. Rank hold CVS as of Q2 2024.

  • Westhampton Capital reported no remaining CVS Health position as of Q2 2024 after selling out during the quarter.
  • Westhampton Capital sold 4,330 CVS Health shares in Q2 2024, an estimated $345K.
  • Westhampton Capital first reported a position in CVS Health in Q2 2019 and held it in 20 quarters.
  • Westhampton Capital's CVS Health position peaked at $880K in Q4 2021.
  • 1,910 funds tracked by Wall St. Rank held CVS Health as of Q2 2024.

Based on Westhampton Capital's 13F filing for Q2 2024, filed 19 Jul 2024.